For Ardelyx Inc. (ARDX), the first quarter of 2024 heralded the dawn of a new era, with Ibsrela's continued upward trajectory and Xphozah's successful launch, propelling the company into commercial prominence.
Ibsrela, the company's flagship drug, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Although the drug was approved by the FDA in September 2019 itself, it was launched in the U.S. only in April 2022.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com